Screening with the activated protein C resistance assay yields significant savings in a patient population with low prevalence of factor V Leiden

Academic Article


  • Testing for factor V Leiden can be performed with a molecular assay or a test for activated protein C resistance. We noted that physicians in our institution tended to order the molecular test 80% of the time, but the prevalence of the mutation in our patient population was less than 10%. Consequently, we decided to introduce the activated protein C resistance assay in house and consistently use it for screening before the more expensive genetic test and to negotiate a discounted charge for the latter at a reference laboratory. After 6 years since these interventions began, the prevalence of an abnormal screening test result remained low (202/2,475 [8.2%]), even among white patients (10.9%). With this simple approach, the cost to test patients for factor V Leiden decreased by more than 90%, while the productivity of our laboratory increased by the introduction of a high-volume, fully automated assay. ¬©American Society for Clinical Pathology.
  • Digital Object Identifier (doi)

    Author List

  • Taylor LJ; Oster RA; Fritsma GA; Tichenor PH; Reed CE; Eiland BM; Hudson CL; Marques MB
  • Start Page

  • 494
  • End Page

  • 499
  • Volume

  • 129
  • Issue

  • 3